Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Zevra Therapeutics
ISIN US4884452065
|WKN A2QLX7
Market cap (in EUR)
721 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 721 m |
| EPS, EUR | 1.86 |
| P/B ratio | 4.0 |
| P/E ratio | 6.5 |
| Dividend yield | 0.00% |
Income statement (2025)
| Revenue, EUR | 94 m |
| Net income, EUR | 69 m |
| Profit margin | 72.87% |
What ETF is Zevra Therapeutics in?
There is 1 ETF which contains Zevra Therapeutics.
| ETF | Weight | Investment focus | Fund size (in m EUR) |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 0.05% | Equity United States Health Care Biotech | 66 |
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.